Obimet GX 4 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 4 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by reducing hepatic glucose production and increasing peripheral insulin sensitivity, contributing to decreased blood glucose levels. The synergistic action of these two agents effectively lowers fasting and postprandial plasma glucose, aiding in the prevention of diabetes-related complications. Obimet GX 4 Tablet PR is typically prescribed when diet, exercise, and monotherapy with either agent alone do not achieve adequate glycemic control. It is essential to monitor blood glucose levels regularly and adjust dosage accordingly to minimize the risk of hypoglycemia and other adverse effects. This medication should be used with caution in patients with renal or hepatic impairment, and contraindications include diabetic ketoacidosis, severe renal dysfunction, and hypersensitivity to any component. Patient adherence to lifestyle modifications alongside pharmacotherapy is crucial for optimal therapeutic outcomes. Always consult a healthcare professional before initiating or adjusting treatment with Obimet GX 4 Tablet PR.